Northern 2 VCT plc (NTV) Ordinary 5p
Sell:53.00p
Buy:56.00p
0
Change:
No change
No change
Market closed |
Prices as at close on 22 November 2024
Prices delayed by at least 15 minutes
|
Switch to live prices
|
- Add to watchlist
- This stock can be held in a
Sell:53.00p
Buy:56.00p
Change:
No change
No change
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
Market closed |
Prices as at close on 22 November 2024
Prices delayed by at least 15 minutes
|
Switch to live prices
|
Sell:53.00p
Buy:56.00p
Change:
No change
No change
Market closed |
Prices as at close on 22 November 2024
Prices delayed by at least 15 minutes
|
Switch to live prices
|
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.
Objective
The Company’s objective is to provide long-term tax-free returns to investors through a combination of dividend yield and capital growth, by investing primarily in unquoted UK businesses which meet the Manager’s key criteria of good growth potential, strong management and potential to generate cash in the medium to long term. The Directors intend that the long-term disposition of the Company’s assets will be approximately 80% in a portfolio of VCT-qualifying unquoted and AIM-quoted investments and 20% in other investments selected with a view to producing an enhanced return while avoiding undue capital volatility, to provide a reserve of liquidity which will maximise the Company’s flexibility as to the timing of investment acquisitions and disposals, dividend payments and share buy-backs.
| Security | Weight |
|---|---|
| Gentronix | 3.23% |
| Grip-Uk (T/A Climbing Hangar) | 3.10% |
| Volumatc Holdings | 2.67% |
| Tutora (T/A Tutorful) | 2.31% |
| Pure Pet Food | 2.16% |
| Project Glow Topco (T/A Currentbody.Com) | 2.12% |
| Newcells Biotech | 2.10% |
| Rockar | 2.06% |
| Biological Preparatons Group | 1.94% |
| Netacea | 1.92% |
Top 10 sectors currently unavailable.
Top 10 countries currently unavailable.
Fee Structure
Management fee of 2.06% p.a. of NAV. Performance fee is 12% of the total return in excess of a hurdle rate. The agreement may be terminated by not less than 12months notice.
Dividend Policy
It is intended that most of the distributable income and realised gains will be paid out. The objective is to pay a dividend at least equivalent to 5% of the opening NAV in each year.
ASSET SPLIT
Trust Manager
Not currently available for this investment trust.
Manager Bio
Not currently available for this investment trust.
Board Of Directors
David GravellsChairman, Thomas Chambers, Cecilia McAnulty, Simon Devonshire, Ranjan Ramparia
Data policy - All information should be used for indicative purposes only. You should
independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete,
and accepts no responsibility for how it may be used.
Objective, holding data, trust manager and bio information, dividend policy, asset split and fee structure are provided by Morningstar.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.